Trial · NCT03190694
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable Angiotensin-converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Treatment. | 6 weeks | % change from baseline | MEAN | |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Glomerular Filtration Rate (GFR) Using Iohexol Clearance | 6 weeks | mL/min per 1.73m2 | MEAN | |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Systolic/Diastolic Blood Pressure | week 0, 3, 6, 12, 15, 18, 24 | Due to several missed visits the no. of analyzed participants is not the same for all visits. | mm Hg | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Body Weight | week 0, 3, 6, 12, 15, 18, 24 | Several participants missed some of their visits | kg | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on 6-keto-Prostaglandin F1 Alpha/Creatinine Ratio | Baseline, Week 6 | Difference in no. of participants at week 6 due to missed visit | pg/mmol | MEAN |
| SECONDARY | Safety of Dapagliflozin vs. Placebo - the Number of Participatns With Hypoglycemic Events and/or Serious Adverse Events | week 0-26 | participants | NUMBER | |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Adenosine/Creatinine Ratio | Baseline, Week 6 | Difference in no. of participants at week 6 due to missed visit | micromol/mmol | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Prostaglandin E2/Creatinine Ratio | Baseline, Week 6 | Difference in no. of participants at week 6 due to missed visit | pg/mmol | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on Thromboxane B2/Creatinine Ratio | Baseline, Week 6 | Difference in no. of participants at week 6 due to missed visit | pg/mmol | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on PGEM/Creatinine Ratio | Baseline, Week 6 | Difference in no. of participants at week 6 due to missed visit | pg/mmol | MEAN |
| SECONDARY | Effect of Dapagliflozin 10 mg/d Compared to Placebo on NTproBNP | Baseline (week 0, week 12), Week 6 + 18 (pooled) | Difference in no. of participants at week 6 due to missed visit | ng/L | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03190694/outcomes